{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:13:14Z","timestamp":1790903594379,"version":"4.1.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":174,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Grant-in-Aid for Clinical Research from the National Hospital Organization"},{"name":"Grant-in-Aid for Clinical Research from the National Hospital Organization"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Patients with noncavitary nodular bronchiectatic (NB) Mycobacterium avium complex pulmonary disease (MAC-PD) are treated intermittently three times per week, although no randomized controlled trials have been conducted comparing three times weekly with daily therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the tolerability, safety, and efficacy of intermittent versus daily treatment in patients with previously untreated noncavitary NB MAC-PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In an open-label study, patients were randomly assigned to the intermittent therapy group receiving clarithromycin 1,000 mg, rifampicin 600 mg, and ethambutol 25 mg\/kg (maximum 1,000 mg) three days per week or the daily therapy group receiving clarithromycin 800 mg, rifampicin 450 mg, and ethambutol 15 mg\/kg (maximum 750 mg) daily for 1 year. The primary endpoint was the proportion of patients requiring modification of the initial treatment regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-one Japanese hospitals participated in the study, enrolling 141 patients between May 2019 and December 2021. The full analysis set included 138 participants (intermittent therapy\u2009=\u200970; daily therapy\u2009=\u200968). There were no significant differences between the intermittent and daily therapy groups in terms of the regimen modification rate (20.0% [14 of 70] vs. 33.8% [23 of 68]; adjusted odds ratio, 0.48; 95% confidence interval, 0.22 to 1.05; P\u2009=\u20090.06) or culture conversion (70.3% vs. 80.0%; P\u2009=\u20090.53), time to culture conversion (28.0 vs. 28.5 d; P\u2009=\u20090.89), improvement in chest CT findings (60.9% vs. 71.0%; P\u2009=\u20090.30), or clarithromycin resistance development (1.4% vs. 0%; P\u2009=\u20091.00). Elevated aspartate aminotransferase (16.9% vs. 41.2%; P\u2009=\u20090.003) and alanine aminotransferase (18.3% vs. 44.1%; P\u2009=\u20090.002) were more common in the daily treatment group, whereas elevated bilirubin (11.3% vs. 1.5%; P\u2009=\u20090.04) and dysgeusia (14.1% vs. 1.5%; P\u2009=\u20090.01) were more common in the intermittent treatment group. The daily treatment group exhibited a greater absolute change in the 36-Item Short Form Health Survey physical aspect score (\u22122.5 points) than the intermittent treatment group (2.1 points) (P\u2009=\u20090.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Intermittent treatment was not significantly better tolerated than daily treatment for noncavitary NB MAC-PD. However, further studies with larger numbers of patients are needed.<\/jats:p>\n                    <jats:p>Clinical trial registered with https:\/\/jrct.mhlw.go.jp\/en-top (jRCTs031190008).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.202406-626oc","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T15:41:27Z","timestamp":1743176487000},"page":"1183-1192","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":8,"title":["Intermittent Versus Daily Therapy for Noncavitary\n                    <i>Mycobacterium avium<\/i>\n                    Complex Pulmonary Disease: An Open-Label Randomized Trial"],"prefix":"10.1093","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4157-1112","authenticated-orcid":false,"given":"Taku","family":"Nakagawa","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, NHO Higashinagoya National Hospital, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6902-9085","authenticated-orcid":false,"given":"Kohei","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, NHO Kyoto Medical Center, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6642-4987","authenticated-orcid":false,"given":"Mari","family":"Miki","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, NHO Osaka Toneyama Medical Center, Osaka, Japan"},{"name":"Department of Internal Medicine, Tokushima Prefecture Naruto Hospital, Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Ohara Healthcare Foundation, Kurashiki Central Hospital, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6181-4284","authenticated-orcid":false,"given":"Ho","family":"Namkoong","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3122-6937","authenticated-orcid":false,"given":"Takanori","family":"Asakura","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine (Laboratory of Bioregulatory Medicine), Kitasato University School of Pharmacy, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8239-9275","authenticated-orcid":false,"given":"Kozo","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0717-7450","authenticated-orcid":false,"given":"Naoki","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6158-7683","authenticated-orcid":false,"given":"Toshiyuki","family":"Kita","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, NHO Kanazawa Medical Center, Ishikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, NHO Ehime Medical Center, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Tsuyuguchi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Clinical Research Center, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kawashima","sequence":"additional","affiliation":[{"name":"Center for Pulmonary Diseases, NHO Tokyo National Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3258-2570","authenticated-orcid":false,"given":"Ayako","family":"Shiozawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, NHO Shibukawa Medical Center, Gunma, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuo","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, NHO Minami Kyoto Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Kato","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, NHO Nagara Medical Center, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4026-7506","authenticated-orcid":false,"given":"Yoshifumi","family":"Kimizuka","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Harada","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, NHO Higashihiroshima Medical Center, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, NHO Okinawa Hospital, Okinawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3723-8445","authenticated-orcid":false,"given":"Akiko M.","family":"Saito","sequence":"additional","affiliation":[{"name":"Clinical Research Center, NHO Nagoya Medical Center, Aichi, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1865-4953","authenticated-orcid":false,"given":"Hiroya","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Clinical Research Center, NHO Nagoya Medical Center, Aichi, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3994-874X","authenticated-orcid":false,"given":"Yoshikazu","family":"Inoue","sequence":"additional","affiliation":[{"name":"Clinical Research Center, NHO Kinki Chuo Chest Medical Center, Osaka, Japan"},{"name":"Department of Internal Medicine, Osaka Anti-Tuberculosis Association Osaka Fukujuji Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4247-6862","authenticated-orcid":false,"given":"Kenji","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, NHO Higashinagoya National Hospital, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"2026012203125794100_bib1","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ijid.2022.10.013","article-title":"Global trends of pulmonary infections with nontuberculous mycobacteria: a systematic review","volume":"125","author":"Dahl","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2026012203125794100_bib2","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ccm.2023.08.012","article-title":"Global epidemiology of nontuberculous mycobacterial pulmonary disease: a review","volume":"44","author":"Prevots","year":"2023","journal-title":"Clin Chest Med"},{"key":"2026012203125794100_bib3","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.3201\/eid2206.151086","article-title":"Epidemiology of pulmonary nontuberculous mycobacterial disease, Japan","volume":"22","author":"Namkoong","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"2026012203125794100_bib4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1513\/AnnalsATS.201607-573OC","article-title":"A laboratory-based analysis of nontuberculous mycobacterial lung disease in Japan from 2012 to 2013","volume":"14","author":"Morimoto","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203125794100_bib5","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1513\/AnnalsATS.201804-236OC","article-title":"Incidence and prevalence of nontuberculous mycobacterial lung disease in a large US managed care health plan, 2008\u20132015","volume":"17","author":"Winthrop","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203125794100_bib6","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1183\/09031936.00149212","article-title":"The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study","volume":"42","author":"Hoefsloot","year":"2013","journal-title":"Eur Respir J"},{"key":"2026012203125794100_bib7","doi-asserted-by":"crossref","first-page":"1602503","DOI":"10.1183\/13993003.02503-2016","article-title":"Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype","volume":"50","author":"Koh","year":"2017","journal-title":"Eur Respir J"},{"key":"2026012203125794100_bib8","doi-asserted-by":"crossref","first-page":"2000535","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur Respir J"},{"key":"2026012203125794100_bib9","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2017-210927","article-title":"British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)","volume":"72","author":"Haworth","year":"2017","journal-title":"Thorax"},{"key":"2026012203125794100_bib10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1086\/515597","article-title":"Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients","volume":"178","author":"Griffith","year":"1998","journal-title":"J Infect Dis"},{"key":"2026012203125794100_bib11","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1086\/313644","article-title":"Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex","volume":"30","author":"Griffith","year":"2000","journal-title":"Clin Infect Dis"},{"key":"2026012203125794100_bib12","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1086\/320512","article-title":"Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease","volume":"32","author":"Griffith","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2026012203125794100_bib13","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1378\/chest.13-2538","article-title":"Macrolide\/azalide therapy for nodular\/bronchiectatic Mycobacterium avium complex lung disease","volume":"146","author":"Wallace","year":"2014","journal-title":"Chest"},{"key":"2026012203125794100_bib14","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1164\/rccm.201408-1545OC","article-title":"Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease","volume":"191","author":"Jeong","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203125794100_bib15","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1164\/rccm.200407-863OC","article-title":"Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease","volume":"172","author":"Griffith","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203125794100_bib16","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1164\/rccm.200603-450OC","article-title":"Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease","volume":"174","author":"Griffith","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203125794100_bib17","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1513\/AnnalsATS.201604-246OC","article-title":"Macrolide-resistant Mycobacterium avium complex lung disease: analysis of 102 consecutive cases","volume":"13","author":"Morimoto","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203125794100_bib18","first-page":"29","article-title":". Guidelines for chemotherapy of pulmonary nontuberculous mycobacterial disease\u20132012 revised version","volume":"88","author":"Nontuberculous Mycobacteriosis Control Committee of the Japanese Society for Tuberculosis; Scientific Assembly for Infection and Tuberculosis of the Japanese Respiratory Society","year":"2013","journal-title":"Kekkaku"},{"key":"2026012203125794100_bib19","doi-asserted-by":"crossref","first-page":"e000434","DOI":"10.1136\/bmjresp-2019-000434","article-title":"Multicentre, open label, randomised controlled trial comparing intermittent versus daily treatment for non-cavitary nodular\/bronchiectatic Mycobacterium avium complex lung disease with rifampicin, ethambutol and clarithromycin (iREC): study protocol","volume":"6","author":"Nakagawa","year":"2019","journal-title":"BMJ Open Respir Res"},{"key":"2026012203125794100_bib20","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203125794100_bib21","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1164\/ajrccm\/145.6.1321","article-title":"A self-complete measure of health status for chronic airflow limitation. The St. George\u2019s Respiratory Questionnaire","volume":"145","author":"Jones","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"2026012203125794100_bib22","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0895-4356(98)00095-X","article-title":"Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan","volume":"51","author":"Fukuhara","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"2026012203125794100_bib23","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.resinv.2021.06.010","article-title":"Lower dose of ethambutol may reduce ocular toxicity without radiological deterioration for Mycobacterium avium complex pulmonary disease","volume":"59","author":"Ando","year":"2021","journal-title":"Respir Investig"},{"key":"2026012203125794100_bib24","first-page":"879","article-title":"Low-dosage ethambutol, less than 12.5 mg\/kg\/day, does not worsen the clinical outcomes of pulmonary Mycobacterium avium and Mycobacterium intracellulare disease: a retrospective cohort study","volume":"50","author":"Watanabe","year":"2022","journal-title":"Infection"},{"key":"2026012203125794100_bib25","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.1128\/AAC.00648-15","article-title":"Response to switch from intermittent therapy to daily therapy for refractory nodular bronchiectatic Mycobacterium avium complex lung disease","volume":"59","author":"Koh","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012203125794100_bib26","doi-asserted-by":"crossref","first-page":"e01003-23","DOI":"10.1128\/aac.01003-23","article-title":"Comparison of treatment outcomes between intermittent and daily regimens in non-cavitary nodular bronchiectatic-type Mycobacterium avium complex pulmonary disease in relation to sputum smear results: a retrospective cohort study","volume":"67","author":"Jung","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012203125794100_bib27","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.rmed.2011.08.004","article-title":"Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease","volume":"105","author":"Mehta","year":"2011","journal-title":"Respir Med"},{"key":"2026012203125794100_bib28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12931-015-0304-5","article-title":"Health-related quality of life is inversely correlated with C-reactive protein and age in Mycobacterium avium complex lung disease: a cross-sectional analysis of 235 patients","volume":"16","author":"Asakura","year":"2015","journal-title":"Respir Res"},{"key":"2026012203125794100_bib29","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12890-018-0686-5","article-title":"Association between six-minute walk test parameters and the health-related quality of life in patients with pulmonary Mycobacterium avium complex disease","volume":"18","author":"Yagi","year":"2018","journal-title":"BMC Pulm Med"},{"key":"2026012203125794100_bib30","doi-asserted-by":"crossref","first-page":"1901300","DOI":"10.1183\/13993003.01300-2019","article-title":"Preliminary validation of the NTM Module: a patient-reported outcome measure for patients with pulmonary nontuberculous mycobacterial disease","volume":"55","author":"Henkle","year":"2020","journal-title":"Eur Respir J"},{"key":"2026012203125794100_bib31","doi-asserted-by":"crossref","first-page":"106515","DOI":"10.1016\/j.rmed.2021.106515","article-title":"Longitudinal validity and prognostic significance of the St George\u2019s Respiratory Questionnaire in Mycobacterium avium complex pulmonary disease","volume":"185","author":"Ogawa","year":"2021","journal-title":"Respir Med"},{"key":"2026012203125794100_bib32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.chest.2023.02.015","article-title":"Patient-reported symptom and health-related quality of life validation and responsiveness during the first 6 months of treatment for Mycobacterium avium complex pulmonary disease","volume":"164","author":"Henkle","year":"2023","journal-title":"Chest"},{"key":"2026012203125794100_bib33","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antituberculosis therapy","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203125794100_bib34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1513\/AnnalsATS.201308-266OC","article-title":"Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study","volume":"11","author":"Miwa","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203125794100_bib35","doi-asserted-by":"crossref","first-page":"106025","DOI":"10.1016\/j.rmed.2020.106025","article-title":"Macrolide resistant Mycobacterium avium complex pulmonary disease following clarithromycin and ethambutol combination therapy","volume":"169","author":"Ito","year":"2020","journal-title":"Respir Med"},{"key":"2026012203125794100_bib36","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1183\/09031936.02.00063702","article-title":"Interpreting thresholds for a clinically significant change in health status in asthma and COPD","volume":"19","author":"Jones","year":"2002","journal-title":"Eur Respir J"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/22\/8\/1183\/66007385\/annalsats_22_8_1183.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/22\/8\/1183\/66007385\/annalsats_22_8_1183.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:13:47Z","timestamp":1769069627000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/22\/8\/1183\/8380552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,1]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202406-626oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"2024-06-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}